Want to see ETST full AI Analyst Report?
Top Page
Earth Science Tech
(OTC:ETST)
Select Model
Select Model
Rating:62Neutral
Price Target:
$0.10
▲(10.00% Upside)
Action:Reiterated
Date:08/20/26
The score is driven mainly by improved financial fundamentals (profitability, positive cash flow, and low leverage), partially offset by weak technical momentum (below major moving averages with bearish MACD). Valuation is favorable on a low P/E, and recent acquisition activity adds a modest positive catalyst but with execution and related-party considerations.
Positive Factors
Low financial leverage
A debt-light balance sheet limits interest burden and refinancing risk, giving ETST greater flexibility to fund operations, absorb volatility and pursue healthcare expansion without relying heavily on external capital.
Negative Factors
Revenue contraction
A sharp top-line decline raises concerns about demand durability, customer retention and the scalability of ETST's operating model. Sustained revenue weakness could eventually pressure margins and limit the benefits of recent expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
A debt-light balance sheet limits interest burden and refinancing risk, giving ETST greater flexibility to fund operations, absorb volatility and pursue healthcare expansion without relying heavily on external capital.
Read all positive factors
Earth Science Tech (ETST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.32M
Dividend YieldN/A
Average Volume (3M)44.92K
Price to Earnings (P/E)7.1
Beta (1Y)2.25
Revenue Growth7.96%
EPS Growth51.14%
CountryUS
Employees77
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.01
Shares Outstanding287,590,880
10 Day Avg. Volume74,750
30 Day Avg. Volume44,925
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.71
Price to Sales (P/S)0.73
P/FCF Ratio21.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)$42.99M
Earth Science Tech Business Overview & Revenue Model
Company Description
Earth Science Tech, Inc. (EST) is a biotechnology firm dedicated to the worldwide development and distribution of nutraceuticals, bioceuticals, and dietary supplements. These offerings aim to support general health, overall well-being, nutrition, ...
Earth Science Tech Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
67
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.96M | 35.70M | 33.12M | 11.95M | 48.54K | 14.12K |
| Gross Profit | 19.34M | 25.49M | 24.30M | 7.83M | 22.06K | -8.52K |
| EBITDA | 4.94M | 3.39M | 3.54M | 1.47M | -382.19K | -219.21K |
| Net Income | 3.89M | 3.63M | 3.25M | 812.14K | -365.40K | 3.17M |
Balance Sheet | ||||||
| Total Assets | 10.37M | 8.97M | 7.07M | 3.88M | 2.73M | 76.94K |
| Cash, Cash Equivalents and Short-Term Investments | 2.82M | 2.16M | 2.12M | 697.72K | 35.76K | 26.94K |
| Total Debt | 353.16K | 96.21K | 401.24K | 246.59K | 974.11K | 780.69K |
| Total Liabilities | 3.01M | 1.93M | 3.22M | 1.63M | 1.61M | 1.88M |
| Stockholders Equity | 7.34M | 7.01M | 3.85M | 2.25M | 1.12M | -1.81M |
Cash Flow | ||||||
| Free Cash Flow | 1.74M | 1.18M | 3.62M | 1.18M | -1.01M | -166.39K |
| Operating Cash Flow | 2.31M | 1.94M | 4.37M | 1.21M | -1.01M | -168.11K |
| Investing Cash Flow | -1.72M | -1.90M | -1.88M | -26.52K | 0.00 | 1.71K |
| Financing Cash Flow | -838.30K | -712.92K | -1.72M | -517.88K | 1.02M | 173.18K |
Earth Science Tech Technical Analysis
Negative
0.09
Price Trends
0.13
Negative
0.14
Negative
0.14
Negative
Market Momentum
>-0.01
Negative
41.35
Neutral
30.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ETST, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.13, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.35 is Neutral, neither overbought nor oversold. The STOCH value of 30.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ETST.
Earth Science Tech Risk Analysis
Earth Science Tech disclosed 38 risk factors in its most recent earnings report. Earth Science Tech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Earth Science Tech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $27.32M | 7.14 | 71.39% | ― | 7.96% | 51.14% | |
59 Neutral | $32.02M | -5.69 | -14.03% | ― | -21.12% | -109.07% | |
58 Neutral | $130.35M | -12.56 | -47.10% | ― | -25.68% | -244.92% | |
52 Neutral | $63.84M | -3.95 | -87.28% | ― | -96.30% | 35.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $51.64M | -3.08 | -21.10% | ― | 489.78% | 45.39% | |
44 Neutral | $20.67M | -0.32 | -96.48% | ― | 33.82% | 34.05% |
* Healthcare Sector Average
ETST
Earth Science Tech
0.09
-0.11
-53.50%
TLPH
Talphera
1.26
0.72
131.19%
RMTI
Rockwell Med
7.92
-10.09
-56.03%
SCYX
SCYNEXIS
5.67
-1.13
-16.59%
CPIX
Cumberland Pharmaceuticals
8.97
6.28
233.46%
COSM
Cosmos Holdings
0.21
-0.62
-74.28%
Earth Science Tech Corporate Events
Business Operations and StrategyM&A Transactions
Earth Science Tech Acquires Zoolzy to Expand Healthcare Operations
Positive
Aug 19, 2026
On August 19, 2026, Earth Science Tech, Inc. announced it had acquired Zoolzy LLC, a Doral, Florida-based wholesale distributor of active pharmaceutical ingredients and finished FDA-approved prescription products operating from a 3,684-square-foot...
Business Operations and StrategyM&A Transactions
Earth Science Tech Expands Footprint With Meduvo Acquisition
Positive
Aug 12, 2026
On August 11, 2026, Earth Science Tech, Inc. entered into an agreement to acquire Meduvo LLC, a compounding pharmacy based in La Verne, California, in a transaction deemed immaterial in size. The deal was structured as a related-party transaction ...
Business Operations and StrategyStock BuybackFinancial DisclosuresRegulatory Filings and Compliance
Earth Science Tech Highlights Transformational Debt-Free Growth Strategy
Positive
Jun 10, 2026
Earth Science Tech, Inc., a Miami-based strategic holding company in the health and wellness space, reported that the fiscal year ended March 31, 2026, was transformational as it advanced a vertically integrated healthcare model spanning telemedic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.